PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This trial is aimed to investigate whether adjuvant PD-1 antibody treatment could improve
survival in locoregionally advanced nasopharyngeal carcinoma compared to best supportive
care.